These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25489477)

  • 1. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia.
    Desmarais JE; Beauclair L; Annable L; Bélanger MC; Kolivakis TT; Margolese HC
    Ther Adv Psychopharmacol; 2014 Dec; 4(6):257-67. PubMed ID: 25489477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?
    Desmarais JE; Beauclair L; Margolese HC
    J Psychopharmacol; 2012 Sep; 26(9):1167-74. PubMed ID: 22651987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.
    Ogino S; Miyamoto S; Miyake N; Yamaguchi N
    Psychiatry Clin Neurosci; 2014 Jan; 68(1):37-49. PubMed ID: 24102938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia.
    Fervaha G; Agid O; Takeuchi H; Lee J; Foussias G; Zakzanis KK; Graff-Guerrero A; Remington G
    Schizophr Res; 2015 Feb; 161(2-3):351-6. PubMed ID: 25471015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
    Haro JM; Salvador-Carulla L
    CNS Drugs; 2006; 20(4):293-301. PubMed ID: 16599647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies.
    Madhusoodanan S; Brenner R; Gupta S; Reddy H; Bogunovic O
    CNS Spectr; 2004 Nov; 9(11):862-7. PubMed ID: 15520608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.
    Gebhardt S; Härtling F; Hanke M; Theisen FM; von Georgi R; Grant P; Mittendorf M; Martin M; Fleischhaker C; Schulz E; Remschmidt H
    Eur Child Adolesc Psychiatry; 2008 Feb; 17(1):44-53. PubMed ID: 17876506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients.
    Drimer T; Shahal B; Barak Y
    Int Clin Psychopharmacol; 2004 Jan; 19(1):27-9. PubMed ID: 15101567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
    Miller DD; McEvoy JP; Davis SM; Caroff SN; Saltz BL; Chakos MH; Swartz MS; Keefe RS; Rosenheck RA; Stroup TS; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):33-43. PubMed ID: 16171976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders.
    König P; Chwatal K; Havelec L; Riedl F; Schubert H; Schultes H
    Neuropsychobiology; 1996; 33(2):80-4. PubMed ID: 8927233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.
    Vanegas-Arroyave N; Caroff SN; Citrome L; Crasta J; McIntyre RS; Meyer JM; Patel A; Smith JM; Farahmand K; Manahan R; Lundt L; Cicero SA
    CNS Drugs; 2024 Apr; 38(4):239-254. PubMed ID: 38502289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.